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Abstract
Background: We have developed magnetite cationic liposomes (MCLs) and applied them as a
mediator of local hyperthermia. MCLs can generate heat under an alternating magnetic field (AMF).
In this study, the in vivo effect of hyperthermia mediated by MCLs was examined using 7,12-
dimethylbenz(a)anthracene (DMBA)-induced rat mammary cancer as a spontaneous cancer model.
Method: MCLs were injected into the mammary cancer and then subjected to an AMF.
Results: Four rats in 20 developed mammary tumors at more than 1 site in the body. The first-
developed tumor in each of these 4 rats was selected and heated to over 43°C following
administration of MCLs by an infusion pump. After a series of 3 hyperthermia treatments, treated
tumors in 3 of the 4 rats were well controlled over a 30-day observation period. One of the 4 rats
exhibited regrowth after 2 weeks. In this rat, there were 3 sites of tumor regrowth. Two of these
regrowths were reduced in volume and regressed completely after 31 days, although the remaining
one grew rapidly. These results indicated hyperthermia-induced immunological antitumor activity
mediated by the MCLs.
Conclusion: Our results suggest that hyperthermic treatment using MCLs is effective in a
spontaneous cancer model.
Background
Magnetic nanoparticles have been widely used in biologi-
cal and medical fields. For instance, magnetic separation
is used to separate certain biomaterials [1] and/or cells
[2,3] by using biologically labeled magnetic beads. In the
medical field, certain types of magnetic dispersion are
used as a contrast agent in magnetic resonance imaging
(MRI) diagnosis [4]. Recently, magnetic nanoparticles
have also been investigated for therapeutic purposes such
as hyperthermic treatment [5].
Hyperthermic treatments have been used for many years,
particularly in anticancer therapy [6]. Typically, there are
2 ranges of targeting temperature used in such treatment.
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directly. Such direct heating methods using needle-type
interstitial antenna materials are effective for inducing
hyperthermia in local regions; however, these technolo-
gies are less effective for larger areas of tissue [7]. Lower
temperatures of approximately 40°C to 43°C are also
associated with an anticancer effect. There are several heat-
ing techniques employed in hyperthermic treatments
using such a temperature range. For example, radiofre-
quency (RF) electric field application is one of the
approved methods for cancer treatment. However, the
effectiveness of this technique varies according to tumor
size and the depth of the tumor region from the body sur-
face. Furthermore, it is sometimes difficult to focus on the
exact location of the tumor [8]. Microwaves, ultrasound
applied as a heating method, are also used for inducing
hyperthermia. For such hyperthermic therapy, magnetic
nanoparticles have also used been used as a heating medi-
ator. The use of these particles is based on fact that such
multidomain ferro- or ferri-magnetic materials are heated
by an alternating magnetic field due to hysteresis losses
[9]. Single domain particles of magnetite can also generate
heat by relaxation loss, not hysteresis loss, under irradia-
tion of alternating magnetic field. Ten nanometer of
diameter is boundary size to allocate particles between
single-domain and multi-domain. Optimal diameter of
magnetic nanoparticle for magnetic nanoparticle-medi-
ated hyperthermia should be investigated in detail.
Our group has pioneered one of these technologies in
order to selectively heat tumor regions [10]. We have
introduced cationic liposome technology in order to
enhance the surface interaction between cells and heating
mediator, and thereby improve its localization. In previ-
ous animal studies, we have demonstrated the efficacy of
hyperthermia induce using magnetite cationic liposomes
(MCLs) [10-12] in several types of tumor model; for
instance, B16 melanoma in mice [13,14], T9 glioma in
rats [12,15], osteosarcoma in hamsters [16], MM46
mouse mammary carcinoma [17], PLS 10 rat prostate can-
cer [18], and VX-7 squamous cell carcinoma in rabbit
tongue [19]. Furthermore, we have described the capabil-
ity of immunologic reactivity in cancer therapy, which was
enhanced by increasing the amount of heat-shock protein
70 (HSP70), following hyperthermic treatment with
MCLs [20-22].
In several transplantable tumor models mentioned above,
the magnetite nanoparticle-mediated hyperthermia pro-
posed by us was found to be very effective for inducing
complete tumor regression. In such models, however,
transplantable cell is an explanted cell. To use the hyper-
thermia for human patients, the effect of the hyperther-
mia should be demonstrated by the use of more practical
tumor model. We focused on oncogene transgenic mice as
spontaneous tumor model and complete tumor regres-
sion of malignant melanoma induced by the oncogene ret
was achieved by the hyperthermia. As a next step, we
investigated here the application to carcinogen-induced
spontaneous tumor models as a practical tumor model
which can simulate practical tumor in the human patient.
7,12-Dimethylbenz(a)anthracene (DMBA)-induced rat
mammary cancer has been widely exploited in cancer
studies for many years, since it was first reported by Hug-
gins et al. [23]. This model is very useful as a spontaneous
cancer model, since blood vessels and lymphoducts sur-
rounding the tumor tissue are likely to simulate human
cancer. In this study, we applied our hyperthermic treat-
ment system with the MCLs to DMBA-induced rat mam-
mary cancer model.
Materials and methods
Animals and mammary tumor models
Eight-week-old Sprague-Dawley (SD) rats were purchased
from the Charles River Laboratory Japan, Inc. (Kanagawa,
Japan). DMBA, purchased from Wako Pure Chemical
Industry, Ltd. (Osaka, Japan), was dissolved in sesame oil,
purchased from ICN Biomedicals, Inc.(CA, USA), and the
concentration was adjusted to 40 mg/mL.
A single dose of 0.5 mL (20 mg DMBA/body) of DMBA/
sesame oil solution was administered to 20 rats via
esophageal intubation. After 10 weeks, 4 rats developed
mammary tumors at more than 1 site in the body. In the
each of these rats, we selected 1 tumor region that
exceeded 10 mm in its long axis and used this for the
experiments.
All animal experiments were conducted in accordance
with the "Guide for the care and use of laboratory animals
of Nagoya University."
Preparation of the MCLs
Magnetite nanoparticles (average diameter, 10 nm) were
purchased from Toda Kogyo Co. (Hiroshima, Japan). N-
(α-trimethyl-ammonioacetyl) didodecyl-D-glutamate
chloride (TMAG) was purchased from Sogo Pharmaceuti-
cal Co. (Tokyo, Japan). Dilauroyl-phosphatidylcholine
(DLPC) and dioleoylphos-phatidylethanolamine
(DOPE) were purchased from NOF Co. (Tokyo, Japan).
The MCLs were prepared by using a previously described
sonication method, with slight modification [10]. Briefly,
1 mL of colloidal magnetite nanoparticle dispersion was
mixed with lipid membrane that consisted of the above-
mentioned phospholipids. Here, the molar ratio of
TMAG, DLPC, and DOPE was 1:2:2. The magnetite con-
centration in the MCLs was determined by measuring iron
content using the potassium thiocyanate method [24].Page 2 of 6
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mg/mL.
Hyperthermia treatment
All 4 rats developed mammary tumors discretely at more
than 1 site in the body. In each rat, we selected the first-
developed tumor for the hyperthermic treatment. The
MCLs were infused gradually into the tumor directly in
approximately 30 minutes by using an infusion pump
(SP100i; World Precision Instruments Inc., FL, USA).
Depending on the tumor volume, we determined the
injection volume and the number of injection sites
required to obtain a uniform distribution of the MCLs.
The applied dose of the MCLs was approximately 2 mg
MCL per mL tumor volume. After the injection, the rats
were subjected to the first hyperthermia treatment for 30
minutes under anesthesia. This treatment was repeated on
the following 2 days. In order to raise the temperature of
the tumor region, the rats were bedded above an irradia-
tion coil. An alternating magnetic field (AMF) was applied
using an AMF radiator (HI-HEATER 5010; DHF Co. Ltd.,
Tokyo, Japan). The magnetic field frequency used was 360
kHz. The temperatures at the surface of the tumor tissue
and rectum were measured by optical fiber probe ther-
mometers (FX-9020; Anritsu Meter Co., Tokyo, Japan).
We started with the power of the AMF irradiator at 1.6 kW,
therefore, SAR value of the MCL was about 175 W/g-mag-
netite. Thereafter, we controlled the temperature of tumor
site by manipulating volume of the irradiating power. We
observed quick response of the heat value by turning of
the irradiating.
Results
Tumor temperature induced by the hyperthermia 
treatment
Figure 1 shows the mean temperature profiles at the site of
the tumor surface and rectum during the hyperthermia
treatment on each treatment day. The temperature of the
tumor region rose depending on the applied AMF,
reached 45°C, and was then maintained at ± 2°C for the
remainder of the treatment. The rectum temperature also
increased gradually but it was lower than that of tumor
surface and was not dependent on the strength of the AMF
field. The temperature difference between two regions was
2–3°C. After termination of the irradiation treatment,
both temperatures decreased immediately.
Tumor volume monitoring
Figure 2 shows the tumor volume profiles of treated
tumors after a series of 3 hyperthermia treatments. In 3 of
the 4 rats, the sizes of the treated tumors were well con-
trolled over a 30-day observation period; the remaining
tumor was controlled for only 3 weeks and regrew there-
after. Figure 3 shows tumor volume profiles after the treat-
ment in each rat. In all 4 rats, we observed multiple
growth of tumors at 1–3 sites in the body. Although those
tumor areas were untreated, their growth volumes were
also measured. In rat #2, there were 3 sites of untreated
sites of the tumor, 1 site of which grew rapidly. The others
were, however, reduced in volume and had regressed
completely after 31 days. In other rats, untreated sites of
tumor were also reduced in volume, or well controlled. In
Temperature profiles of the surface of the tumor (closed cir-cl s) and rectum (open circles) during t  hyperthermia tr atmen  at day 1 (A), 2 (B), and 3 (C)Figur  1
Temperature profiles of the surface of the tumor 
(closed circles) and rectum (open circles) during the 
hyperthermia treatment at day 1 (A), 2 (B), and 3 
(C). Data points and bars represent the mean and SD of 4 
treated rats.Page 3 of 6
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shown after it sizes comes out to be recognizable. Without
any treatment, DMBA-induced tumors grew rapidly on
the average basis of 4 individual rats.
Discussion
Human breast cancer usually originates in the ductal
region and the DMBA-induced mammary tumor model
exhibits the same origin [25]. Therefore, this rat model is
considered to be a good animal model of human breast
cancer.
Figure 1 shows that the temperature increases in the
tumor region were slightly slower than those previously
reported by our group [16]. We believe that this difference
is due to the cooling effect of the vascular systems that
developed in the spontaneous tumor tissue. However, it
was possible to raise the temperature of the tumor region
during the treatment periods, and we therefore followed
former protocols in this study.
After the course of treatment, all 4 rats that developed
multiple mammary tumors exhibited tumor regression in
the immediate region of the treated site. In spite of this
being our first attempt to apply our protocol to a hyper-
thermia effect similar to that obtained for a transplanted
tumor model that we reported previously.
As shown in Fig. 2, 1 of the 4 rats exhibited rapid regrowth
the tumor within 2 weeks. Another rat exhibited slight
regrowth. These results appear to indicate certain inade-
quacies of the present treatment protocol as applied to the
spontaneous tumor model, despite it being applicable for
the previously investigated transplanted tumor model.
One of the possible reasons for this discrepancy is consid-
ered to be the highly developed vasculature and/or lym-
phoid system in the spontaneous tumors that were not
Tumor growth profiles for each rat after 3 treatments (A, Rat #1; B, #2; C, #3; and D, #4)Figure 3
Tumor growth profiles for each rat after 3 treat-
ments (A, Rat #1; B, #2; C, #3; and D, #4). Closed 
squares: treated tumor; open squares: untreated tumor. Tri-
angles represent treatment days.
Tumor growth profiles at the treatment sites after 3 treat-mentsFigure 2
Tumor growth profiles at the treatment sites after 3 
treatments. Triangles represent treatment days.Page 4 of 6
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lature might create localized regions of tissue that do not
reach sufficiently high temperatures. The developed nutri-
tion/elimination systems also appear to promote the
clearance of the administered MCLs from the injected
region. Therefore, it is suggested that the treatment proto-
col should be optimized, particularly with respect to the
dose of MCL, the temperature during treatment, and the
number of repeat treatments. Given such optimization, it
is expected that such regrowths would be repressed. How-
ever, tumor growth was remarkably controlled in the early
going compared with untreated group of rats (Fig. 4).
Therefore, we believe our hyperthermia system will be
capable in the future.
In the case of the carcinogen-induced spontaneous tumor
models, it is considered that the sites of origin in the ani-
mal body are heterogeneous. Indeed, in our experiments,
tumor growth at several untreated sites progressed regard-
less of the treatment. Meanwhile, we also observed some
tumor shrinkage at sites where no MCLs had been admin-
istered, and which had therefore not been exposed to the
hyperthermic conditions during the treatment. These
shrinkages were maintained stably for more than 50 days
without additional treatment. These results suggest the
presence of an immunological antitumor reaction
induced by the MCL-mediated hyperthermia, as observed
previously with a transplanted tumor model [20]. These
responses are believed to be linked to a specific antigen,
such as HSP70, that is generated by necrosis of the directly
heated tumor cells [21,22]. We also reported the mecha-
nisms of immune reactions which are induced by our
hypertharmia system in the previous study [26,27]. We
demonstrated the mechanism of immunological reaction
which is enhanced by HSP70 dumped from dead tissue
with our hyperthermia system. It was also revealed that
cancer specific DC maturation was induced by our treat-
ment system.
In the present study, we therefore confirmed the advan-
tage of our hyperthermic procedure in the treatment of
carcinogen-induced spontaneous tumors. In the future, it
will be necessary to optimize operational conditions in
order to enhance the hyperthermic effect in the spontane-
ous tumor model.
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